Top Biotechnology Startups in 2027

We are a Sequencing platform with instruments at the center of our products and offerings and an entire ecosystem of products being built around those. We are targeting research applications in the short term and clinical applications in the long run.

Natera® is a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease. Our team includes clinicians, scientists, biostatisticians, researchers, and talented laboratory professionals from around the globe. Natera develops and commercializes non-invasive methods for analyzing DNA. We operate a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California, and offer a host of proprietary genetic testing services. Specialties: Non-Invasive Prenatal Testing (NIPT), Single Gene Diseases, Preimplantation Genetic Screening (PGS)/Diagnosis (PGD), Biopsy Training, Multi-Disease Carrier Screening, Bioinformatics, Miscarriage Testing, Genetic Counseling, Non-Invasive Paternity Testing, and Genetics Hours:9am-5pm PST, Monday-Friday Address: 201 Industrial Road Suite 410 San Carlos, CA 94070 Phone: (650) 249-9090 Email: [email protected]

Saphetor is a personalized medicine diagnostics company working to improve outcomes for patients by offering clinicians data-driven solutions for making better diagnoses and selecting optimal therapies. To do this, Saphetor is pioneering the automation of the currently laborious and disparate processes required for genome-scale analyses and annotation of data from NGS – Next Generation Sequencing. Saphetor already has created an innovative approach for aggregating and efficiently interrogating more than 8 billion individual annotations from multiple external sources. This work, which leverages proprietary algorithms, affords Saphetor the power needed to rapidly identify pathogenic variants with higher confidence (i.e. fewer false positives and fewer false negatives) than competitors. Saphetor sells access to its technology platform for automated NGS data analysis and annotation and also offers value added content (i.e. reports written by molecular geneticists) to medical geneticists.

Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from living organisms. By developing a comprehensive database of chemical biodiversity, Enveda aims to accelerate the discovery of new medicines.

Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space. The Schrödinger platform is deployed by industry leaders worldwide for drug discovery, as well as for materials science in fields as diverse as aerospace, energy, semiconductors, oil and gas, automotive, and electronics displays. The platform also powers our own drug discovery efforts, from target identification to hit discovery to lead optimization. It also drives our research collaborations to develop novel medicines for critical public health needs. With more than 150 Ph.D. scientists on our team, we invest heavily in R&D. We’ve published over 400 peer-reviewed papers that demonstrate the strength of our physics-based approaches, and we’re continually pushing the limits of computer modeling.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

Designial delivers dedicated capability centers, commercial acceleration pods, and advanced operational solutions for high-growth US Healthcare & Life Sciences companies (including Biotech, Pharma, MedTech, HealthTech, and Insurtech) and Private Equity portfolio platforms. We partner with executive leaders across Commercial Operations, Clinical R&D, and Digital Systems to eliminate scaling bottlenecks and deliver client-aligned capability teams.

Informuta is an infectious disease intelligence company that forecasts drug resistance trajectories to guide antibiotic selection with precision and quantify treatment-emergent resistance risk for the first time. Informuta uses proprietary AI and novel predictive genomic biomarkers to give clinicians the confidence to choose therapies that won’t fail their most vulnerable patients - transforming antibiotic prescribing from reactive to predictive and empowering smarter, future-proofed decisions.